CASI Pharmaceuticals, Inc. (CASIF) stock
Close on Oct 19, 2026Market cap –P/E –Yield –
CASI Pharmaceuticals, Inc. saw revenue fall 27.4% to $20.71M over fiscal 2025. Free cash flow was -$20.77M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $20.71M
- Net income
- -$48.06M
- EPS, diluted
- -$2.59
- Free cash flow
- -$20.77M
Trading
- Previous close
- $0.10
- Open
- $0.10
- Day's range
- $0.10 – $0.10
- Volume
- 681
- Average volume (20 days)
- 1,407
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CASIF | S&P 500 | Difference | CASIF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.3% | +0.6% | −22.9 pts | ||
| 3 months | -39.7% | +3.4% | −43.1 pts | ||
| Year to date | -88.2% | +13.3% | −101.5 pts | ||
| 1 year | -94.2% | +16.6% | −110.9 pts | ||
| 3 years | -97.2% | +86.4% | −183.6 pts | -69.7% | +23.1% |
| 5 years | -99.1% | +81.9% | −181.0 pts | -61.0% | +12.7% |
| 10 years | -99.3% | +318.9% | −418.1 pts | -38.9% | +15.4% |
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CASI Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About CASI Pharmaceuticals
Pharmaceutical Preparations
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for hematology-oncology, autoimmune diseases, and organ transplant rejection. Following corporate restructuring and the divestiture of its China-focused pipeline rights, the firm primarily operates as a clinical-stage drug developer advancing CID-103, an anti-CD38 monoclonal antibody. It also holds rights to therapies including EVOMELA, FOLOTYN, CNCT19, and CB-5339, alongside generic melphalan. Products are targeted toward medical institutions and oncology patients, with distribution agreements spanning pharmaceutical distributors and healthcare partners.
Company profile, executives and historyCASI Pharmaceuticals stock: common questions
What is CASI Pharmaceuticals's stock price?
CASIF closed at $0.10 on Oct 19, 2026, up 0.00% on the day.
What is CASIF's P/E ratio?
CASI Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$2.59), so it has no meaningful P/E ratio.
How much revenue does CASI Pharmaceuticals make?
CASI Pharmaceuticals reported revenue of $20.71M for fiscal 2025, down 27.4% from a year earlier.
Does CASI Pharmaceuticals pay a dividend?
No. CASI Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has CASIF stock performed over the past year?
Including dividends, CASIF returned -94.2% over the past year, against +16.6% for the S&P 500.
Who are CASI Pharmaceuticals's competitors?
Companies most similar to CASI Pharmaceuticals by business, industry and size include CBIO, APLM, PRLD, VRDN, NAMS.
See a number that looks wrong?